Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 2, 1997, Pages 449-453

  Stein, Daniel S ^a   Drusano, George L ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INDINAVIR;

ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HALF LIFE TIME; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031039602     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.2.449     Document Type: Article

References (24)

1. D'Argenio, D. Z., and A. Schumitzky. 1992. ADAPT II. A program package for simulation, identification, and optimal experimental design. Users manual. Biomedical Simulations Resource, University of Southern California. Los Angeles.
2. + cell turnover. Nature 375: 194-195. (Letter.)
3. Drusano, G. L., F. M. Balis, S. R. Gitterman, and P. A. Pizzo. 1994. Quantitative relationships between zidovudine exposure exposure and efficacy and toxicity. Antimicrob. Agents Chemother. 38:1726-1731.
4. Drusano. G. L., G. J. Yuen, J. S. Lambert, M. Seidlin, R. Dolin, and F. T. Valentine. 1992. Quantitative relationships between dideoxyinosine exposure and surrogate markers of response in a phase I trial. Ann. Intern. Med. 116:562-566.
5. Embretson, J., M. Zupancic, J. L. Ribas, A. Burke, P. Racz, K. Tenner-Racz, and A. T. Hause. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362: 359-362.
6. Fox, C. H., K. Tenner-Racz, P. Racz, A. Firpo, P. A. Pizzo, and A. S. Fauci. 1991. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J. Infect. Dis. 164:1051-1057.
7. Gelman, R., S. C. Cheng, P. Kidd, M. Waxdal, and J. Kagan. 1993. Assessment of the effects of instrumentation, monoclonal antibody, and fluorochrome on flow cytometric immunophenotyping: a report based on 2 years of the NIAID DAIDS flow cytometry quality assessment program. Clin. Immunol. Immunopathol. 66:150-162.
8. Hill, A. V. 1910. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol. 40:4-7.
9. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
10. Holford, N. H. G., and L. B. Sheiner. 1981. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6:429-453.
11. + cell turnover. Nature 375:193-194. (Letter.)
12. Mulder, J., N. McKinney, C. Christopheron, J. Sninsky, L. Greenfield, and S. Kwok. 1994. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32:292-300.
13. Pantaleo, G., C. Graziosi, L. Butini, P. A. Pizzo, S. M. Schnittman, D. P. Kotler, and A. S. Fauci. 1991. Lymphoid organs as the major reservoirs for human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88:9838-9842.
14. Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358.
15. Pantaleo, G., C. Graziosi, and A. S. Fauci. 1993. The immunopathogenesis of human immunodeficiency virus infection. N. Engl. J. Med. 328:327-335.
16. + cell turnover. Nature 375:195. (Letter.)
17. Rocci, M. L., and W. J. Jusko. 1983. LAGRAN program area and moments in pharmacokinetic analysis. Comput. Programs Biomed. 16:203-216.
18. Sale, M., L. B. Sheiner, P. Volberding, and T. F. Blaschke. 1993. Zidovudine response relationships in early human immunodeficiency virus infection. Clin. Pharmacol. Ther. 54:556-566.
19. Sprent, J., and D. F. Tough. 1994. Lymphocyte life-span and memory. Science 265:1395-1400.
20. + cell turnover. Nature 375:194. (Letter.)
21. Steigbigel, R. T., P. Berry, J. Mellors, D. McMahon, H. Teppler, D. Stein, G. Drusano, P. Deutsch, K. Yeh, C. Hildebrand, M. Nessly, E. Emini, and J. Chodakewitz. 1996. Efficacy and safety of the HIV protease inhibitor Indinavir sulfate (MK-639) at escalating dose, abstr. 146. In Abstracts of the 3rd Conference on Human Retroviruses and Opportunistic Infections.
22. Stein, D. S., D. G. Fish, J. A. Bilello, S. L. Preston, G. L. Martineau, and G. L. Drusano. 1996. A 24 week open label phase 1 evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10:485-492.
23. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Donhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
24. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.